The Adoption Gap in Healthcare (Part 2): The Evidence Barrier
Why Clinical Proof Is Necessary but Not Sufficient
Data drives strategy in every industry; in healthcare, data drives outcomes.
Ask any healthcare marketer what their most powerful commercial asset is, and they will almost certainly say: the data. Clinical evidence, outcomes studies, peer-reviewed publications. These are the currency of credibility in healthcare. Without evidence, there is no conversation.
But here is what I have learned through years of commercializing in MedTech: evidence alone does not drive adoption. I have seen technologies with robust randomized controlled trial data fail to move beyond a handful of pilot sites. I have watched guideline-supported tests struggle to achieve meaningful utilization years after launch. The evidence existed. The adoption did not follow.
The reason is that evidence is not a single thing. It is a layered and target-dependent construct. Yet many commercial teams treat it as if it were uniform.
Evidence does not speak for itself. Someone must translate it, stage it, and deliver it to the right target segment at the right time during their decision journey.
The Evidence Ladder
Clinical evidence is a ladder, with each rung representing a different stage of proof that unlocks a different type of buyer. Understanding where your evidence sits on this ladder and what it will and will not unlock is one of the most important strategic assessments a marketing leader can make.
At the base of the ladder are early clinical data: feasibility studies, analytical validation, and early-access program results. This evidence is sufficient to engage innovators, early adopters, and thought leaders from the academic medical centers who are willing to take an evidence-informed bet on a promising technology.
The next rung is prospective clinical data and real-world evidence from comparable institutions. This is where the majority of health system decisions are made. A CMO or medical director does not only want to know that your technology worked in a clinical trial, but they also want to know that it worked in an institution that looks like theirs, in a patient population that resembles their own.
In other words, clinical validity is not enough; they want to see clinical utility.
The next level of value comes from peer-reviewed publications and eventually guideline inclusion. These are the evidence milestones that move the conservative majority, the technology skeptics who require institutional permission before they will change their practice. Guideline inclusion in particular is a watershed moment, often unlocking payer coverage and system-level adoption simultaneously. However, this can be a long journey for many new products, and leaders must plan the path carefully.
At the top of the ladder sits real-world outcomes data from the health system's own patient population, the most persuasive evidence of all, because it is theirs.
Understanding Stakeholders’ Motivation
Evidence barriers are compounded by the fact that different stakeholders within the same health system are asking fundamentally different evidence questions, and most commercial teams may not be carefully thinking about them.
The clinical champion, the oncologist, pathologist, or specialist who believes in your technology wants granular clinical data: sensitivity, specificity, clinical utility, and impact on treatment decisions. The Chief Medical Officer wants comparative effectiveness data and evidence of patient outcome improvement. The Chief Medical Information Officer wants interoperability evidence and data governance. The CFO is looking for the ROI of the investment.
Presenting the same evidence package to all of these audiences is not just inefficient, it is often counterproductive. A clinical data deck shown to a CMO without an outcomes framing signals that the commercial team does not understand the questions that matter at the executive level.
The Role of KOLs in Evidence Strategy
Key opinion leaders (KOLs) are often treated as a late-stage commercial asset, brought in to speak at conferences or endorse a product once it is already in the market. This is a missed opportunity. KOLs are most valuable when they are engaged early and positioned as genuine scientific partners, not marketing spokespersons.
The most effective KOL programs I have built and participated in share a common architecture. They identify clinicians who are genuinely curious about the science and willing to generate real-world data. They invest in co-authorship of publications and presentations, not just endorsements. They create feedback loops between KOLs' insights and product development. And they recognize that a credible KOL speaking to a peer carries more weight than any in-house collateral a marketing team can produce.
Real-world evidence generation, driven through structured KOL partnerships, is how the gap between clinical trial data and health system adoption is bridged. It is not a medical affairs function alone; it is a commercial imperative.
KOL programs are not relationship programs. At their best, they are evidence translation programs, turning clinical data into peer-validated narratives that has higher impact than any marketing campaign.
Barrier Audit: Questions To Ask
Where does your evidence sit on the evidence ladder, and which buyer segments does it currently unlock?
Do you have target-specific evidence packages for clinical, executive, and administrative stakeholders?
Are your KOLs generating real-world data, or just providing endorsements?
How far are you from guideline inclusion, and do you have a strategy to accelerate it?
Can you show the health system outcomes data from an institution that resembles theirs?
Next in the series, Part 3: The Economic Barrier. Why the CFO and the CMO are having completely different conversations, and why marketing needs to be present in both.